Center for Transport Oncophysics

拟议的运输肿瘤物理中心（CTO）是五个机构之间的合作计划。主要研究者是Mauro Ferrari博士（UTHSC-H），高级合作研究者是Steven Curley博士（MDACC）。因此，所提出的CTO的第一个总体具体目标是构建用于理解癌症的“参考系统”，其中多维“单位向量”是跨基本生物载体集合的传输物理学的微分定律，因为它们呈现自己并在肿瘤发生中演变（即，运输物理学）。第二个总体具体目标是证明CTO内开发的新型系统和方法（多级系统、纳米梭、碳纳米管、金胶体、口服给药载体）在相应动物模型中的治疗效果。拟议CTO将具有以下功能：1.一个单一的科学框架（<$transfer oncopysics <$as the differential，和生物屏障作为运输节点）; 2.一个综合的多尺度方法（我们的数学，工程探针和成像仪器都是多尺度的，在这里被用来研究生物屏障的多尺度架构）反映在共享的核心和所有项目平台可用作其他项目的核心; 3. A？双重意图操作方法，用于基本发现的工程运输探针也被用于展示创新的治疗方式，以解决两个癌症焦点集群领域未解决的临床需求; 4.癌症病灶和动物模型的综合选择。第一个重点集群是肝癌，包括原发性和转移性（项目1-2），第二个是结直肠癌（项目3），结直肠癌的肝转移方面有着令人信服的联系，并在Fidler博士的指导下选择了真诚再现人类疾病的统一动物模型。通过试点项目机制，将在CTO的整个业务过程中开展进一步的调查，以解决运输肿瘤物理学的互补和协同方面。

The proposed Center for Transport OncoPhysics (CTO) is a collaborative program among five institutions. The Principal Investigator is Dr. Mauro Ferrari (UTHSC-H) and the Senior Co-Investigator is Dr. Steven Curley (MDACC). Thus, the first overall specific aim of the proposed CTO is to construct a ¿reference system¿ for the understanding of cancer, where the multi-dimensional ¿unit vectors¿ are the differential laws of transport physics across a fundamental set of biobarriers as they present themselves and evolve in tumorigenesis (i.e., ¿transport oncophysics¿). The second overarching Specific Aim is to demonstrate the therapeutic efficacy of the novel systems and approaches developed within the CTO (multi-stage systems, nanoshuttles, carbon nanotubes, gold colloids, oral administration carriers) in the respective animal models. The proposed CTO will feature: 1. A single scientific framework (¿transport oncophysics¿ as the differential, and biological barriers as the transport nodes); 2. An integrated ¿multiple multi-scale¿ approach (our mathematics, engineered probes, and imaging instrumentation are all multiscale, and are here employed to study the multiscale architecture of the biological barriers) reflected in shared cores and all project platforms being available to serve as cores for other projects; 3. A ¿dual-intent¿ operational approach, with the engineered transport probes used for basic discovery also being employed for the demonstration of innovative therapeutic modalities addressing unsolved clinical needs in two cancer focus cluster areas; 4. An integrated choice of cancer focus and animal models. The first focus cluster is liver cancer, both primary and metastatic (Projects 1-2), the second is colorectal cancer (Projects 3), with cogent connections being the liver metastasis aspect of colorectal cancer, and the choice of unified animal models that sincerely recapitulate human diseases, under the guidance of Dr. Fidler. Further investigations that address complementary and synergistic aspects of transport onco-physics will be launched throughout the operations of the CTO by means of the Pilot Projects mechanism.